🇺🇸 Colloidal pectin bismuth particles A quadruple therapy in United States

Colloidal pectin bismuth particles A quadruple therapy (Colloidal pectin bismuth particles A quadruple therapy) regulatory status in United States.

Marketing authorisation

FDA

  • Status: approved

Colloidal pectin bismuth particles A quadruple therapy in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Colloidal pectin bismuth particles A quadruple therapy approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Colloidal pectin bismuth particles A quadruple therapy in United States?

Xijing Hospital of Digestive Diseases is the originator. The local marketing authorisation holder may differ — check the official source linked above.